Abstract:Aim:Glyoxalase I (GLOI), a glutathione (GSH)-dependent enzyme, is overexpressed in tumor cells and related to multi-drug resistance in chemotherapy, making GLOI inhibitors as potential anti-tumor agents. But the most studied GSH analogs exhibit poor pharmacokinetic properties. The aim of this study was to discover novel non-GSH analog GLOI inhibitors and analyze their binding mechanisms.Methods:Mouse GLOI (mGLOI) was expressed in BL21 (DE3) pLysS after induction with isopropyl-β-D-1-thiogalactopyranoside and purified using AKTA FPLC system. An in vitro mGLOI enzyme assay was used to screen a small pool of compounds containing carboxyl groups. Crystal structure of the mGLOI-inhibitor complex was determined at 2.3 Å resolution. Molecular docking study was performed using Discovery Studio 2.5 software package.Results:A natural compound 18-β-glycyrrhetinic acid (GA) and its derivative carbenoxolone were identified as potent competitive non-GSH analog mGLOI inhibitors with Ki values of 0.29 μmol/L and 0.93 μmol/L, respectively. Four pentacyclic triterpenes (ursolic acid, oleanolic acid, betulic acid and tripterine) showed weak activities (mGLOI inhibition ratio <25% at 10 μmol/L) and other three (maslinic acid, corosolic acid and madecassic acid) were inactive. The crystal structure of the mGLOI-GA complex showed that the carboxyl group of GA mimicked the γ-glutamyl residue of GSH by hydrogen bonding to the glutamyl sites (residues Arg38B, Asn104B and Arg123A) in the GSH binding site of mGLOI. The extensive van der Waals interactions between GA and the surrounding residues also contributed greatly to the binding of GA and mGLOI.Conclusion:This work demonstrates a carboxyl group to be an important functional feature of non-GSH analog GLOI inhibitors.

Structure-Based Design of N-(5-Phenylthiazol-2-yl)acrylamides As Novel and Potent Glutathione S-Transferase Omega 1 Inhibitors

Discovery of a Potent Chloroacetamide GPX4 Inhibitor with Bioavailability to Enable Target Engagement in Mice, a Potential Tool Compound for Inducing Ferroptosis in Vivo.

Exploring NAG‐thiazoline and Its Derivatives As Inhibitors of Chitinolytic Β‐acetylglucosaminidases

Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site

Design and structural optimization of thiadiazole derivatives with potent GLS1 inhibitory activity

Structural basis for 18-β-glycyrrhetinic acid as a novel non-GSH analog glyoxalase I inhibitor

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP

Structure-guided Activity Restoration of the Silkworm Glutathione Transferase Omega GSTO3-3.

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

Structure-Guided Activity Restoration Of The Silkworm Glutathione Transferase Omega Gsto3-3

Amino acid tethered benzoxazolone as highly potent inhibitors of O-glycosylation

Unraveling Potential Glyoxalase-I Inhibitors Utilizing Structure-Based Drug Design Techniques

New insights into the molecular mechanisms of glutaminase C inhibitors in cancer cells using serial room temperature crystallography

A novel method for screening the glutathione transferase inhibitors

Rational Design, Synthesis, and Mechanism of (3 S,4 R)-3-Amino-4-(difluoromethyl)cyclopent-1-ene-1-carboxylic Acid: Employing a Second-Deprotonation Strategy for Selectivity of Human Ornithine Aminotransferase over GABA Aminotransferase

Ligandability Assessment of Human Glutathione Transferase M1-1 Using Pesticides as Chemical Probes

Design, synthesis and biological evaluation of N-(4-alkoxy-3-(1H-tetrazol-1-yl)phenyl) heterocyclic aromatic amide derivatives as xanthine oxidase inhibitors

The Design and Synthesis of N-Xanthone Benzenesulfonamides As Novel Phosphoglycerate Mutase 1 (PGAM1) Inhibitors

Structure-Based Design of Anticancer Prodrug PABA/NO.